The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment.

MLA

Suda, Goki, et al. “The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-Infected Hemodialysis Patients Who Failed to Respond to NS5A and Protease Inhibitor Treatment.” Internal Medicine (Tokyo, Japan), vol. 58, no. 7, Apr. 2019, pp. 943–47. EBSCOhost, https://doi.org/10.2169/internalmedicine.2077-18.

APA

Suda, G., Nakai, M., Sho, T., Kimura, M., Shimazaki, T., Maehara, O., Shigesawa, T., Suzuki, K., Nakamura, A., Ohara, M., Umemura, M., Kawagishi, N., Baba, M., Natsuizaka, M., Morikawa, K., Ogawa, K., & Sakamoto, N. (2019). The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment. Internal Medicine (Tokyo, Japan), 58(7), 943–947. https://doi.org/10.2169/internalmedicine.2077-18

Chicago

Suda, Goki, Masato Nakai, Takuya Sho, Megumi Kimura, Tomoe Shimazaki, Osamu Maehara, Taku Shigesawa, et al. 2019. “The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-Infected Hemodialysis Patients Who Failed to Respond to NS5A and Protease Inhibitor Treatment.” Internal Medicine (Tokyo, Japan) 58 (7): 943–47. doi:10.2169/internalmedicine.2077-18.